Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Response rates (Confirmed/unconfirmed with ≥16 weeks follow-up)

From: Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status

  Overall population EGFR/ALK wild-type population
  All cohorts Combined cohort: D10–20 q4w or q2w + T1 All cohorts Combined cohort: D10–20 q4w or q2w + T1
  n/N (%) 95% CI n/N (%) 95% CI n/N (%) 95% CI n/N (%) 95% CI
All patients 21/84 (25) 16–36 11/39 (28) 15–45 21/73 (29) 19–41 11/34 (32) 17–51
PD-L1+ (≥25%) 7/20 (35) 15–59 3/9 (33) 8–70 7/17 (41) 18–67 3/9 (33) 8–70
PD-L1- (<25%) 11/49 (22) 12–37 6/23 (26) 10–48 11/45 (24) 13–40 6/19 (32) 13–57
PD-L1- (0%) 9/27 (33) 17–54 6/12 (50) 21–79 9/26 (35) 17–56 6/11 (55) 23–83
All 2L patients 15/32 (47) 29–65 7/16 (44) 20–70 15/31 (48) 30–67 7/15 (47) 21–73
PD-L1+ (≥25%) 6/8 (75) 35–97 2/3 (67) 9–99 6/8 (75) 35–97 2/3 (67) 9–99
PD-L1- (<25%) 7/18 (39) 17–64 4/11 (36) 11–69 7/17 (41) 18–67 4/10 (40) 12–74
PD-L1- (0%) 6/8 (75) 35–97 4/5 (80) 28–100 6/8 (75) 35–97 4/5 (80) 28–100
  1. 2L, second line: 1 prior line of therapy, receiving D+T in second line